Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective reduced by Citigroup from $193.00 to $178.00 in a research note released on Wednesday morning, Benzinga reports. Citigroup currently has a buy rating on the biotechnology company’s stock.
A number of other research firms have also recently weighed in on ASND. Morgan Stanley raised their price target on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an equal weight rating in a report on Thursday, May 16th. The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a buy rating in a research note on Tuesday, August 13th. StockNews.com downgraded Ascendis Pharma A/S from a hold rating to a sell rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. decreased their price objective on Ascendis Pharma A/S from $174.00 to $165.00 and set an overweight rating for the company in a report on Wednesday. Finally, Bank of America boosted their target price on Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a buy rating in a research note on Wednesday. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average price target of $187.08.
Read Our Latest Analysis on Ascendis Pharma A/S
Ascendis Pharma A/S Price Performance
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of ASND. Gilbert & Cook Inc. increased its stake in shares of Ascendis Pharma A/S by 8.4% in the fourth quarter. Gilbert & Cook Inc. now owns 2,838 shares of the biotechnology company’s stock worth $357,000 after acquiring an additional 220 shares during the period. Jump Financial LLC acquired a new stake in Ascendis Pharma A/S during the 4th quarter worth about $1,681,000. Massachusetts Financial Services Co. MA raised its stake in shares of Ascendis Pharma A/S by 20.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company’s stock valued at $191,346,000 after buying an additional 254,749 shares during the last quarter. First Turn Management LLC acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at about $19,092,000. Finally, Quadrant Capital Group LLC boosted its position in Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 151 shares in the last quarter.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Further Reading
- Five stocks we like better than Ascendis Pharma A/S
- Following Congress Stock Trades
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- Compound Interest and Why It Matters When Investing
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- Using the MarketBeat Stock Split Calculator
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.